Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
11.32
-0.12 (-1.05%)
At close: Sep 9, 2025, 4:00 PM
11.31
-0.01 (-0.12%)
After-hours: Sep 9, 2025, 7:00 PM EDT
Arcus Biosciences Stock Forecast
Stock Price Forecast
The 7 analysts that cover Arcus Biosciences stock have a consensus rating of "Buy" and an average price target of $20.71, which forecasts a 82.95% increase in the stock price over the next year. The lowest target is $13 and the highest is $30.
Price Target: $20.71 (+82.95%)
Analyst Consensus: Buy
* Price targets were last updated on Aug 7, 2025.
Analyst Ratings
The average analyst rating for Arcus Biosciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 1 |
| Buy | 6 | 6 | 6 | 6 | 6 | 5 |
| Hold | 1 | 1 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 10 | 11 | 11 | 11 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $26 → $25 | Buy | Maintains | $26 → $25 | +120.85% | Aug 7, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $24 → $22 | Buy | Maintains | $24 → $22 | +94.35% | May 9, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $15 → $13 | Hold | Maintains | $15 → $13 | +14.84% | May 8, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $29 → $26 | Buy | Maintains | $29 → $26 | +129.68% | May 7, 2025 |
| Barclays | Barclays | Buy Maintains $29 → $14 | Buy | Maintains | $29 → $14 | +23.67% | Apr 23, 2025 |
Financial Forecast
Revenue This Year
236.48M
from 258.00M
Decreased by -8.34%
Revenue Next Year
131.14M
from 236.48M
Decreased by -44.54%
EPS This Year
-3.84
from -3.14
EPS Next Year
-4.22
from -3.84
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 260.4M | 236.3M | |||
| Avg | 236.5M | 131.1M | |||
| Low | 219.0M | 43.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.9% | -0.1% | |||
| Avg | -8.3% | -44.5% | |||
| Low | -15.1% | -81.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.47 | -2.22 | |||
| Avg | -3.84 | -4.22 | |||
| Low | -4.21 | -4.95 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.